Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White
Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.
|The following article features coverage from the American Society of Clinical Oncology (ASCO) 2018 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.|
Black men with metastatic castration-resistant prostate cancer (mCRPC) experience a greater PSA response to treatment with abiraterone and prednisone compared with white men, investigators reported at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.1
In the prospective multicenter Abi Race trial (ClinicalTrials.gov Identifier: NCT01940276), in which 50 black and 50 white men with mCRPC were treated with abiraterone and prednisone (abiraterone 1000 mg/day, prednisone 10 mg/day), the median PSA progression-free survival (PFS) was significantly higher among black patients compared with white patients (16.6 vs 11.5 months), according to investigators Daniel J. George, MD, of Duke University Medical Center in Durham, North Carolina, and colleagues.
The arm that included black patients also had numerically greater proportions of patients who had at least a 30%, 50%, and 90% PSA decrease (86% vs 76%, 76% vs 66%, and 48% vs 38%, respectively). The races did not differ with respect to median radiographic PFS (both 16.8 months), the trial's primary outcome of interest.
Read more of Cancer Therapy Advisor's coverage of the American Society of Clinical Oncology (ASCO) 2018 meeting by visiting the conference page.
- George DJ, Heath EI, Sartor AO, et al. Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP). J Clin Oncol. 2018: 36, (suppl; abstr LBA5009). Presented at 2018 ASCO Annual Meeting; June 1-5, 2018; Chicago, IL.